Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis

Abstract Estimating survival in amyotrophic lateral sclerosis (ALS) is challenging due to heterogeneity in clinical features of disease and a lack of suitable markers that predict survival. Our aim was to determine whether scoring of upper or lower motor neuron weakness is associated with survival. With this objective, 161 ALS subjects were recruited from two tertiary referral centres. Scoring of upper (UMN) and lower motor neuron (LMN) signs was performed, in addition to a brief questionnaire. Subjects were then followed until the censorship date. Univariate analysis was performed to identify variables associated with survival to either non-invasive ventilation (NIV) or death, which were then further characterized using Cox regression. Results showed that factors associated with reduced survival included older age, bulbar and respiratory involvement and shorter diagnostic delay (all p < 0.05). Whole body LMN score was strongly associated with time to NIV or death (p ≤0.001) whereas UMN scores were poorly associated with survival. In conclusion, our results suggest that, early in disease assessment and in the context of other factors (age, bulbar, respiratory status), the burden of LMN weakness provides an accurate estimate of outcome. Such a scoring system could predict prognosis, and thereby aid in selection of patients for clinical trials.

[1]  J. Fiore,et al.  Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  M. Kiernan,et al.  Study of motor asymmetry in ALS indicates an effect of limb dominance on onset and spread of weakness, and an important role for upper motor neurons , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[3]  H. Mitsumoto,et al.  Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? , 2014, The Lancet Neurology.

[4]  W. Robberecht,et al.  The phenotypic variability of amyotrophic lateral sclerosis , 2014, Nature Reviews Neurology.

[5]  L. H. van den Berg,et al.  A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[6]  E. Beghi,et al.  Long‐term survival in amyotrophic lateral sclerosis: A population‐based study , 2014, Annals of neurology.

[7]  A. Al-Chalabi,et al.  Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  A. Chiò,et al.  Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  Albert Ludolph,et al.  Mechanisms, models and biomarkers in amyotrophic lateral sclerosis , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[10]  M. Swash,et al.  Controversies and priorities in amyotrophic lateral sclerosis , 2013, The Lancet Neurology.

[11]  Mamede de Carvalho,et al.  Phrenic nerve studies predict survival in amyotrophic lateral sclerosis , 2012, Clinical Neurophysiology.

[12]  V. Meininger,et al.  Predicting Survival of Patients with Amyotrophic Lateral Sclerosis at Presentation: A 15-Year Experience , 2012, Neurodegenerative Diseases.

[13]  R. Sica,et al.  Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis , 2012, European journal of neurology.

[14]  Y. Kuroiwa,et al.  Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: A multicenter study in Japan , 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[15]  M. Swash Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  T. Hanafusa,et al.  Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  M. Sabatelli,et al.  Uncovering amyotrophic lateral sclerosis phenotypes: Clinical features and long-term follow-up of upper motor neuron-dominant ALS , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[18]  S. Petri,et al.  Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis , 2011, Muscle & nerve.

[19]  A. Chiò,et al.  Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[21]  C. Tan,et al.  Survival and prognostic factors of motor neuron disease in a multi-ethnic Asian population , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[22]  Pamela A McCombe,et al.  Effects of gender in amyotrophic lateral sclerosis. , 2010, Gender medicine.

[23]  M. Carone,et al.  Patients who survive 5 years or more with ALS in Olmsted County, 1925–2004 , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  M. Hernán,et al.  Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study , 2010, BMC neurology.

[25]  M. Swash,et al.  Association of paraspinal and diaphragm denervation in ALS , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[26]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[27]  A. Forbes,et al.  Clinical phenotypes and natural progression for motor neuron disease: Analysis from an Australian database , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[28]  S. Petri,et al.  Onset and spreading patterns of upper and lower motor neuron symptoms in ALS , 2008 .

[29]  E. Beghi,et al.  Predictors of long survival in amyotrophic lateral sclerosis: A population-based study , 2008, Journal of the Neurological Sciences.

[30]  L. D. Val,et al.  Factores pronósticos y supervivencia en la enfermedad de neurona motora , 2007 .

[31]  J. Ravits,et al.  Focality of upper and lower motor neuron degeneration at the clinical onset of ALS , 2007, Neurology.

[32]  S. Appel,et al.  Predictability of disease progression in amyotrophic lateral sclerosis , 2006, Muscle & nerve.

[33]  V. Meininger,et al.  Diaphragmatic dysfunction and dyspnoea in amyotrophic lateral sclerosis. , 2000, The European respiratory journal.

[34]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[35]  S H Appel,et al.  Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. , 1995, Brain : a journal of neurology.

[36]  P. Andres,et al.  Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis , 1988, Neurology.

[37]  C. Pérez-Lázaro,et al.  [Pronostic factors and survival in motor neuron disease]. , 2007, Neurología.